BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 10, 2011
 |  BioCentury  |  Emerging Company Profile

PanOptica: Dropping in on VEGF

PanOptica VEGF receptor inhibitor avoids the needle for wet AMD

Most of the next generation of treatments for age-related macular degeneration are focusing on reducing or eliminating intravitreal injections, which are burdensome to patients and present safety risks. PanOptica Inc. believes its PAN-90806, a small molecule selective inhibitor of VEGF receptor, will be among the best approaches because it has a validated mechanism, is formulated as an easy-to-use eyedrop and has high bioavailability at the disease site.

Last week, PanOptica raised $30 million in a series A round and licensed exclusive, worldwide rights to PAN-90806 for ophthalmic diseases from OSI Pharmaceuticals Inc., a subsidiary of Astellas Pharma Inc.

"We have shown in animal models of wet AMD that topically administered PAN-90806 works as well as anti-VEGF antibodies delivered via injection," said Paul Chaney, PanOptica's president, CEO and co-founder.

Lucentis ranibizumab, the standard of care for wet AMD, is...

Read the full 695 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >